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Abstract
Retinoic acid-related Orphan Receptor alpha (RORa; NR1F1) is a widely distributed nuclear receptor involved in several
(patho)physiological functions including lipid metabolism, inflammation, angiogenesis, and circadian rhythm. To better
understand the role of this nuclear receptor in liver, we aimed at displaying genes controlled by RORa in liver cells by
generating HepG2 human hepatoma cells stably over-expressing RORa. Genes whose expression was altered in these cells
versus control cells were displayed using micro-arrays followed by qRT-PCR analysis. Expression of these genes was also
altered in cells in which RORa was transiently over-expressed after adenoviral infection. A number of the genes found were
involved in known pathways controlled by RORa, for instance LPA, NR1D2 and ADIPOQ in lipid metabolism, ADIPOQ and PLG
in inflammation, PLG in fibrinolysis and NR1D2 and NR1D1 in circadian rhythm. This study also revealed that genes such as
G6PC, involved in glucose homeostasis, and AGRP, involved in the control of body weight, are also controlled by RORa.
Lastly, SPARC, involved in cell growth and adhesion, and associated with liver carcinogenesis, was up-regulated by RORa.
SPARC was found to be a new putative RORa target gene since it possesses, in its promoter, a functional RORE as evidenced
by EMSAs and transfection experiments. Most of the other genes that we found regulated by RORa also contained putative
ROREs in their regulatory regions. Chromatin immunoprecipitation (ChIP) confirmed that the ROREs present in the SPARC,
PLG, G6PC, NR1D2 and AGRP genes were occupied by RORa in HepG2 cells. Therefore these genes must now be considered
as direct RORa targets. Our results open new routes on the roles of RORa in glucose metabolism and carcinogenesis within
cells of hepatic origin.
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Introduction
Nuclear receptors are transcription factors, which are crucial in
development and play major roles in metabolism and homeostasis
(see [1] for review). Besides the classical nuclear receptors, which
bind hormones and organic compounds, inverse genetic and
genome sequencing approaches have identified a large number of
nuclear receptor genes in the human and mouse genomes (see [2]
for review). The function of some of these new receptors has been
clarified in recent years and their ligands characterized. For others,
however, their exact role is not understood and the nature of their
ligand(s), if any, is still a matter of debate. Understanding in detail
their function(s) is of major importance with potential crucial
repercussions in the fields of metabolism, pharmacology and
carcinogenesis.
Retinoic acid receptor-related Orphan Receptor a (RORa;
NR1F1; [3,4]) is one of these nuclear receptors. It has been cloned
by virtue of its strong homology with the Retinoic Acid Receptor
[5]. Most often RORa binds DNA as a monomer to specific sites
called RORa response elements (ROREs). These elements consist
of a 6-bp AT-rich sequence preceding the half-core PuGGTCA
motif; they will be designated (A/T rich)6PuGGTCA in the rest of
the manuscript [6]. The Rora gene generates four isoforms
(RORa1–4), which differ in their N-terminal region [7]. Some
putative ligands have been proposed for RORa: the natural
hormone melatonin, synthetic thiazolidinediones and cholesterol
derivatives, but some data are controversial and the nature of the
RORa ligand(s) remains unclear [8,9]. A spontaneous deletion
within the Rora gene that prevents translation of the RORa ligand
binding domain has been identified in the staggerer mouse (see [10]
for review). Like the mice in which the Rora gene has been
knocked-out by homologous recombination, the homozygous
staggerer (Rora
sg/sg) mutant mice suffer from severe cerebellar ataxia
caused by massive neurodegeneration of Purkinje cells (see [10] for
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22545review). Moreover, analysis of the phenotype of the Rora
sg/sg mouse
has revealed the importance of RORa in regulating the
inflammatory and immune responses [11,12], in modulating
atherosclerosis susceptibility [13,14], and in post-ischemic angio-
genesis [15].
RORa stimulates the transcription of the gene for the NFkB
inhibitor IkB [11]. The gene encoding apolipoprotein A-I, a major
component of high density lipoproteins, has also been shown to be
controlled by RORa in rats [14]. We and others have provided
evidence that RORa may participate in the control of a-
fetoprotein [16], apolipoprotein C-III [17], apolipoprotein A-V
[18], and fibrinogen-ß gene expression in liver [19]. Recent
findings have indicated that the Rora gene is up-regulated by
hypoxia via a Hypoxia Inducible Factor-1 (HIF-1)-dependent
mechanism [20]. RORa also regulates HIF-1 at the transcrip-
tional level [21]. These data have brought new information about
the possible roles of RORa in (patho)physiological processes such
as lipid metabolism, response to inflammation, angiogenesis and
carcinogenesis where hypoxia plays an important role. The
implication of RORa in these important functions has been
recently demonstrated (see [22,23] for reviews).
It is also known that RORa, together with another nuclear
receptor Rev-erba (NR1D1; [4]), participates in the control of the
circadian clock and that there are interactions of physiological
significance between the circadian clock and metabolism ([24] and
see [22] for review).
Large-scale techniques, such as characterization of the tran-
scriptome of cells or organs, are powerful tools to display genes
controlled by a transcription factor. In the case of ROR, they have
been used to identify genes differentially expressed in the liver of
mice lacking functional RORa and RORc proteins and in the
liver of wild-type control mice. These studies have demonstrated
that RORa and RORc control genes involved in phase I and II
metabolism [25].
In the present study we have used micro-arrays to analyze the
modifications of the transcriptome of HepG2 human hepatoma
cells upon stable over-expression of RORa. This approach,
combined with electrophoretic mobility shift assays (EMSAs),
reporter gene expression and chromatin immunoprecipitation
(ChIP), revealed several novel hepatic RORa target genes with
interest in physiology and pathophysiology.
Results
Over-expression of RORa1 alters gene expression in
HepG2 human hepatoma cells
We used a DNA micro-array technique, which we had
previously validated by monitoring the effect of hypoxia on gene
expression in HepG2 cells (data not shown) to display genes whose
expression is controlled by RORa in HepG2 cells. We analyzed
RNA prepared from HepG2 cells stably transfected with the
pCMX-hRORa1 vector and over-expressing human RORa.
HepG2 cells stably transfected with the pCMX empty vector
were used as control. To ascertain that the stably transfected cells
over-produced RORa, we first monitored by qRT-PCR the levels
of Rora mRNA. The Rora mRNA levels were found to be largely
increased (15.0+/22.0 fold, n=3, p,0.01) in pCMX-hRORa1
transfected cells (Fig. 1).
To confirm that the recombinant RORa protein is over-
produced and functional in the stably transfected cells, we
measured the mRNA levels of the Rev-erba (NR1D1) nuclear
receptor, whose gene is a known target of RORa [26,27]. The
level of NR1D1 mRNA was significantly higher (2.1+/20.2 fold,
n=3, p,0.01) in cells over-expressing RORa than in control cells.
Taken together, these data indicated that HepG2 hepatoma cells
stably transfected with the pCMX-hRORa1 vector over-produced
biologically active RORa protein.
Large-scale analysis using DNA micro-arrays was then per-
formed on RNA prepared from HepG2 cells stably over-
expressing RORa and from control cells. The results showed that
expression of a number of genes was altered by over-expression of
RORa. Most of the modulated genes were assigned and are listed
in Table 1. All genes but two were up-regulated. Sequences not
assigned to a known gene are given in Supporting Information S2.
We checked the validity of our DNA micro-array analysis by
measuring by qRT-PCR the mRNA levels of SPARC, PLG, G6PC,
NR1D2 (Rev-erbb), and AGRP on aliquots of the RNA samples used
in the micro-array analysis. The qRT-PCR results showed a
statistically significant increase in the mRNAs for SPARC, PLG,a n d
G6PC incellsover-expressingRORa (Fig.1)andthus confirmed the
Figure 1. qRT-PCR analysis of expression of several of the
genes found to be up-regulated in HepG2 cells over-express-
ing RORa upon micro-array analysis. Aliquots of the RNA samples
from stably-transfected HepG2 cells over-expressing RORa1 and from
stably transfected control cells that have been analyzed by the DNA
micro-array technology were submitted to qRT-PCR analysis for
measuring the levels of Rora, SPARC, PLG, G6PC, NR1D2, and AGRP
mRNAs. The mRNA levels were normalized to the 36B4 mRNA level.
Results corresponding to HepG2 cells over-expressing RORa1 (black
bars) are given relatively to the control cells (grey bars). Values refer to
the means +/2 S.E.M. of the fold changes (n=3 independent pools of
transfected cells). *: P,0.05, **: P,0.01, ***: P,0.001 between RORa1
over-expressing and control cells.
doi:10.1371/journal.pone.0022545.g001
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NR1D2 and AGRP were not statistically significant, they showed a
tendency towards an increase in RORa-over-expressing cells
(Fig. 1). Our approaches thus displayed a subset of genes specifically
controlled by RORa in HepG2 human hepatoma cells.
Expression of the genes revealed in our micro-array
analysis is stimulated in HepG2 cells infected with an
adenovirus over-expressing RORa1
In order to avoid possible artifacts inherent in the use of stably
modified cultured cells over-expressing a transcription factor, we
thought important to further check, by a complementary
approach, the validity of the results obtained in stable transfec-
tants. We infected HepG2 cells with an adenoviral vector
expressing the RORa1 cDNA (Ad-RORa), and monitored by
qRT-PCR the expression of several of the genes identified in stably
transfected cells. As controls, HepG2 cells were infected with an
adenoviral vector expressing the Green Fluorescent Protein (Ad-
GFP) cDNA. The levels of the Rora, SPARC, PLG, G6PC, NR1D2
and AGRP mRNAs were measured by qRT-PCR 24 h, 48 h and
72 h after infection of HepG2 cells with either Ad-RORa or
control Ad-GFP. These experiments showed that the expression
of all the analyzed genes including NR1D2 and AGRP was
Table 1. Micro-array analysis of the effects of a stable RORa over-expression on gene expression in HepG2 cells.
Gene symbol Gene description Genbank accession Feature Number Fold change Mean±SEM Pvalue
Up-regulated
PLG plasminogen NM_000301 12618 25.84
27.24
29.65
27.5861.11 6.40E-15
1.39E-19
2.15E-19
RORA RAR-related orphan
receptor A
NM_134260 31288 12.98
16.45
13.83
14.4261.04 3.73E-20
7.29E-21
2.33E-20
LPA lipoprotein, Lp(a) NM_005577 31776 10.08
8.40
9.60
9.3660.5 3.59E-12
1.02E-14
2.47E-16
FBXL17 F-box and leucine-rich
repeat protein 17
BC018548 391 5.49
2.69
2.19
3.4661.03 1.13E-08
9.20E-05
4.88E-05
G6PC glucose-6-phosphatase,
catalytic subunit
NM_000151 19594 2.78
3.03
2.61
2.8060.12 6.73E-07
4.06E-07
3.26E-06
SPARC secreted protein, acidic,
cysteine-rich (osteonectin)
NM_003118 4259 2.84
2.23
2.03
2.3760.24 1.13E-09
5.19E-07
5.64E-06
AGRP agouti related protein
homolog (mouse)
NM_001138 21543 2.74
2.66
1.44
2.2860.42 1.89E-03
6.19E-04
1.34E-01
NR1D2 nuclear receptor subfamily 1,
group D, member 2
BC015929 31530 2.08
2.91
1.68
2.2260.36 3.04E-05
2.02E-08
1.86E-03
SMOC1 SPARC related modular
calcium binding 1 (SMOC1)
NM_022137 32907 2.10
1.75
2.68
2.1860.27 2.54E-06
2.09E-04
5.11E-09
HEPN1 associated with
liver cancer
NM_001037558 34970 1.81
2.18
2.50
2.1660.20 2.58E-03
1.52E-05
9.65E-07
MLLT7 myeloid/lymphoid or
mixed-lineage leukemia
translocated to 7
NM_005938 42837 1.91
2.00
2.22
2.0460.09 4.52E-03
1.02E-03
9.14E-05
Down-regulated
LGI2 leucine-rich repeat LGI
family, member 2
NM_018176 24947 0.19
0.36
0.37
0.3160.06 1.88E-05
4.57E-04
2.46E-03
ADIPOQ adiponectin, C1Q and
collagen domain
containing
NM_004797 36194 0.34
0.17
0.17
0.2360.06 3.21E-03
6.58E-04
4.51E-04
HepG2 cells were stably transfected with the pCMX-hRORa1 expression vector or with the pCMX insertless vector as a control. Total RNAs were extracted and mRNA
levels were compared between these two experimental conditions with Agilent micro-arrays. This analysis revealed several genes whose expression was up-regulated or
down-regulated by at least 2 fold in cells over-expressing RORa as compared to control cells. The results relative to sequences corresponding to known genes are
shown. The gene symbols, gene description, genbank accession numbers and feature numbers on micro-arrays are given in columns 1 to 4. Gene expression levels in
RORa over-expressing cells are expressed relatively to those in control cells. Results are given in column 5 as fold changes and in column 6 as the means of these fold
changes +/2 S.E.M. (n=3 independent pools of transfected cells). Pvalues generated by the micro-array analysis are shown in column 7. It refers to the statistical
significance of the differences between cells over-expressing RORa and control cells (all Pvalues are less than 0.01 except one over three for AGRP). Results
corresponding to one spot/Feature Number representative of two are shown for PLG.
doi:10.1371/journal.pone.0022545.t001
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production of RORa in HepG2 cells (Fig. 2). The level of NR1D1
mRNA was also increased in response to adenoviral-mediated
over-expression of RORa (data not shown).
In summary, it appears that our results were generally
corroborated in two cellular models (stably-transfected and
adenovirus-infected cells), and using two techniques for measuring
gene expression: DNA micro-arrays and qRT-PCR. Therefore
our results converge to show that expression of the subset of genes
listed in Table 1 is controlled by RORa in HepG2 cells. Although
the expression of the genes for NR1D2 and AGRP was not
significantly affected by RORa1 over-expression in stable
transfectants, because of sample variability (Fig. 1), the effect of
RORa1 on these two genes became clearly visible after
adenovirus-mediated over-expression (Fig. 2).
The promoter of the human SPARC gene contains a
functional RORE
Our present study points to several novel genes as being
regulated, at least in part, by RORa in cells of hepatic origin.
However, it is important to know whether these genes are direct or
indirect targets for RORa.
In this context, and because of the crucial importance of
SPARC in several cell functions in different organs, including liver,
both during normal life and in carcinogenesis (see [28] for review),
we chose to test if the SPARC gene was directly regulated by
RORa. We detected one putative RORE (59-TGTTCTGG-
GTCA-39) between nucleotides 2285 and 2274 relative to the
transcription start site in the human SPARC promoter [29]. We
searched if this putative RORE was conserved in other species and
we found that this element is totally conserved in Chimpanzee,
Orangutan and partially conserved (59-TGTTCTAGGTGA-39)i n
Mouse, Rat, and Horse. We investigated whether this putative
RORE was functional in terms of RORa binding and transcrip-
tional control in HepG2 cells and if consequently, the SPARC gene
was susceptible to be directly controlled by RORa.
We first performed EMSAs to determine if the RORa protein
bound to the putative SPARC-RORE. As shown in Fig. 3, a
complex was formed between RORa and the labeled oligonucle-
otide. Specificity of binding was confirmed by competition
experiments using unlabelled oligonucleotides covering the wild-
type or mutated SPARC-RORE, the fibrinogen-ß-RORE [19], and
an unrelated oligonucleotide containing the Hypoxia Response
Element of the EPO gene [20]. These experiments clearly
demonstrated that RORa specifically bound to the DNA element
present between 2285 and 2274 in the promoter of the human
SPARC gene.
To determine if the SPARC-RORE was functionally active, we
carried out transient transfections in HepG2 cells with plasmids
containing a luciferase reporter gene placed under the control of
the herpes simplex virus thymidine kinase (Tk) promoter either
alone or in association with three tandem copies of the SPARC-
RORE. Co-transfection of these plasmids with a vector overex-
pressing the RORa cDNA showed that presence of the three
ROREs resulted in a large increase in RORa-induced luciferase
activity (Fig. 4). It may be concluded that RORa activates
transcription upon binding to the RORE element present in the
SPARC gene promoter.
Taken together, the results from the EMSAs and the transient
tranfections showed that the SPARC-RORE is functionally active
in HepG2 cells. They indicated that the SPARC gene is, at least in
part, under the direct transcriptional control of RORa. Conse-
quently SPARC must now be considered as a RORa target gene in
HepG2 cells.
The regulatory regions of most of the genes disclosed in
the micro-array analysis contain putative ROREs
To determine whether some of the other human genes
displayed in our micro-arrays were putative direct RORa target
genes, we searched their regulatory regions (promoter and
intragenic regions) for DNA sequences resembling the (A/T
rich)6PuGGTCA motif characteristic of ROREs and found in the
SPARC promoter. For this purpose we used the Genomatix-based
matrices described in Materials and Methods. This analysis was
carried out on ten of the human genes that we had identified (PLG,
FBXL17, G6PC, AGRP, NR1D2, SMOC1, HEPN1, MLLT7, LGI2,
ADIPOQ). We found that the regulatory regions of nine out of
these ten genes contained at least one DNA sequence matching the
RORE consensus (Table 2). Importantly, several of these putative
Figure 2. qRT-PCR analysis of expression of RORa-regulated
genes in HepG2 cells over-expressing RORa1 following adeno-
viral infection. HepG2 cells were infected with recombinant
adenoviral vectors allowing expression of either RORa1 or GFP as a
control. Total RNAs were extracted at 24 h, 48 h and 72 h following
adenoviral infection. Aliquots were then analyzed by qRT-PCR for
measuring the levels of Rora, SPARC, PLG, G6PC, NR1D2, and AGRP
mRNAs. The mRNA levels were normalized to the 36B4 mRNA level.
Results corresponding to HepG2 cells over-expressing RORa1 (black
bars) are given relatively to the control cells over-expressing GFP (grey
bars). Values refer to the means +/2 S.E.M of the fold changes (n=3
independent experiments). ns: non statistically significant, *: P,0.05,
**: P,0.01, ***: P,0.001 between RORa1 over-expressing and control
cells.
RORa Targets in HepG2 Cells
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Human (Table 2 and Supporting Information S3). This evolu-
tionary conservation favors the hypothesis that the putative
ROREs are physiologically relevant. Search of the whole human
genome for ROREs using Genomatix-based matrices revealed a
frequency of 1.41 ROREs per 1000 bp. In view of this high
frequency, it appeared necessary to determine whether the genes
displayed in our micro-arrays were indeed direct RORa targets in
vivo.
Chromatin immunoprecipitation demonstrates that
RORa binds in vivo to the regulatory regions of the genes
identified in the micro-array analysis
We carried out ChIP in HepG2 cells using an anti-RORa
antibody. Immunoprecipitated DNA fragments were submitted to
qPCR using primers specific for SPARC, PLG, G6PC, NR1D2 and
AGRP. The regions amplified contained the ROREs that we had
identified using the Genomatix matrices. Results are shown in
Fig. 5. For all five genes examined, HepG2 cells stably over-
producing RORa1 yielded a statistically significant ChIP
enrichment when the anti-RORa specific antibody was used as
compared to the nonspecific IgG (Fig. 5A). No difference was
detected in HepG2 cells producing normal amounts of RORa for
SPARC, G6PC, NR1D2 and AGRP (Fig. 5B). The PLG gene alone
showed a statistically significant enrichment (Fig. 5B). The
specificity of the ChIP was further demonstrated by the fact that
an irrelevant region located 9300 bp downstream of the
transcription start site in the human SPARC promoter [29] was
not enriched by immunoprecipitation with the anti-RORa
antibody (Fig. 5). Taken together, our data show that the ROREs
that we identified in the SPARC, PLG, G6PC, NR1D2 and AGRP
genes can bind RORa in vivo in the context of HepG2 cells over-
expressing RORa. Therefore, these genes must be considered as
novel targets for RORa.
Figure 3. RORa binds to a RORE in the promoter of the human
SPARC gene. EMSAs were performed by using a radiolabeled double-
stranded oligonucleotide containing the DNA sequence corresponding
to region 2289 to 2264 of the human SPARC promoter (SPARC-RORE
probe). The probe was incubated alone or with 1 ml of unprogrammed
reticulocyte lysate as controls (lanes 1 and 2, respectively), or with 1 ml
of RORa1-programmed lysate (lanes 3–15). Competition assays were
carried out by incubating the SPARC-RORE probe with the RORa1-
programmed lysate in the presence of unlabeled double-stranded
oligonucleotides corresponding to the wild-type SPARC-RORE (lanes 4–
6), or the mutated SPARC-ROREm (lanes 7–9), or the RORE of the human
fibrinogen-ß gene (lanes 10–12), or the hypoxia response element of the
EPO gene (lanes 13–15) at a 4-, 10-, or 40-fold molar excess. The arrow
points to the complex formed upon binding of RORa to the SPARC-
RORE probe. Sequences of the oligonucleotides are given in the lower
part of the figure. The RORE sequence is written in bold. Nucleotides
written in lowercase were added for convenience.
doi:10.1371/journal.pone.0022545.g003
Figure 4. RORa activates transcription through the (2285/
2274) RORE of the SPARC promoter in HepG2 cells. HepG2 cells
were transiently cotransfected in 12-well plates with 666 ng/well of the
pRORE(hSPARC)3x-Tk-Luc luciferase reporter vector or with 666 ng/well
of the pTk-Luc control luciferase reporter vector and with increasing
amounts (0-, 166.5-, or 333-ng/well) of pCMX-hRORa1 expression
vector. The systematic cotransfection with 83 ng/well of the pRL-Tk
normalization vector allowed the normalization of the luciferase
activities obtained with the reporter vectors. The total amount of
transfected DNA was kept constant to 1082 ng/well by adding the
pCMX insertless vector. The normalized activities of the vectors in the
presence of pCMX-hRORa1 were expressed relatively to that in the
absence of this expression vector. Results are given as means +/2 S.E.M.
(n=6 independent experiments). ***: P,0.001 between cells transfect-
ed with pRORE(hSPARC)3x-Tk-Luc and cells transfected with pTk-Luc.
doi:10.1371/journal.pone.0022545.g004
RORa Targets in HepG2 Cells
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Very little is known on the biological function of RORa and its
target genes in cells of hepatic origin. To our knowledge, the only
previous such study of RORa target genes is a micro-array
analysis comparing the liver of RORa-mutant staggerer mice with
that of wild-type mice [25]. Because RORa is widely expressed,
these mice exhibit a broad spectrum of physiological defects, such
as abnormalities in eating behavior, inability to maintain correct
body temperature, to move properly, etc… Therefore, when
analyzing the liver phenotype of the staggerer mice, it is difficult to
sort out the direct effects of the mutation on liver cells from
indirect ones that may find their origin outside of the liver. Such
difficulty does not exist when examining cultured human
hepatoma cells, where the effect of RORa on gene expression is
necessarily direct. Therefore in order to increase our knowledge on
RORa function in human hepatic cells, we analyzed, using DNA
micro-arrays, the changes in the expression of genes induced by a
stable over-expression of this transcription factor in HepG2
human hepatoma cells. We thus identified SPARC, PLG, G6PC,
NR1D2 and AGRP as RORa targets in hepatoma cells. The results
obtained with the micro-arrays were confirmed by qRT-PCR. We
cannot however exclude that our approach did not display all the
RORa-sensitive genes present in HepG2 cells. Interestingly, the
genes whose expression was modulated in cells stably over-
expressing RORa also showed altered expression in cells in which
RORa was transiently over-expressed following infection with a
RORa adenoviral vector. The convergence of these two
approaches strengthened the conclusion that RORa modulates
the expression of the genes that we identified. The fact that the
regulatory region of most, if not all of these genes, possessed a
DNA sequence very close to the RORE consensus lent further
support to the idea that they are indeed RORa target genes. This
hypothesis was confirmed by ChIP experiments showing that the
ROREs were occupied by RORa in the cells. In addition, we
showed that in the case of the SPARC promoter, binding of RORa
led to transactivation in HepG2 cells. However, we could not
detect a correlation between the level of chromatin occupancy by
RORa and its target gene expression. We may hypothesize that
RORa affects transcription both directly and indirectly, possibly
by changing protein-protein interaction networks.
We showed that expression of the Rev-erba gene is higher in
HepG2 cells in which RORa is over-expressed. Rev-erba
(NR1D1) is a nuclear receptor, whose gene is known to be a
direct target for RORa [26,27]. This strongly reinforces our
findings. It is then reasonable to think that the genes listed in
Table 1 are indeed modulated by RORa in hepatic cells. Some of
the RORa-modulated genes are involved in physiological
functions such as lipid metabolism (LPA, NR1D2, ADIPOQ also
known as adiponectin) and inflammation (ADIPOQ, PLG), but also in
related cardiovascular diseases such as atherosclerosis
[30,31,32,33]. Interestingly, it is well known that RORa plays a
role in these functions (see [23] for review). Moreover, PLG,
another RORa target gene displayed by the present study, is
involved in fibrinolysis, wound healing, tumor growth and
metastasis [34]. Interestingly, PAI-1, another component of the
fibrinolytic system, and fibrinogen-ß, one of the chains of the
coagulation factor fibrinogen, are also RORa targets [19,35].
These data strongly suggest that RORa is involved in the fine
control of coagulation/fibrinolysis with potential impacts on
processes such as wound healing, tumor growth, metastasis and
atherothrombosis.
Table 2. Identification of putative ROREs in the genes displayed by the micro-array analysis.
Gene symbol Putative RORE sequence Position in the human gene
RORE conservation in other
species
PLG tctcatgtAAGTCAacaacatcc from 26t o+17 (promoter) Chimpanzee, Rhesus macaque,
Mouse, Rat
FBXL17 attattgtAAGTCAccgtaagag intragenic (intron 2) Chimpanzee
FBXL17 ctaaacaaAGGTCAcgccagtac intragenic (intron 2) Chimpanzee, Rat, Dog, Chicken
G6PC cagtattcAGGTCAacccagccc from 266 to 244 (promoter) Mouse, Rat, Dog
AGRP aagaattcGGGTCAaggacattg from 2140 to 2118 (promoter) Chimpanzee, Rat, Dog, Cow
NR1D2 tggctcttAGGTCAaagcggtgg from 2388 to 2366 (promoter) Rhesus macaque, Dog
NR1D2 gcatgaccAGGTCAaccttttaa intragenic (intron 5) Chimpanzee, Rhesus macaque,
Mouse, Dog, Cow, Zebrafish
HEPN1 gcataactATGTCAggaagacag from 2260 to 2238 (promoter) -
MLLT7 tctcaatcTGGTCAcctacacga from 2944 to 2922 (promoter) Chimpanzee, Rhesus macaque,
Dog
LGI2 catgacttTGGTCAagtcactta intragenic (intron 2) Chimpanzee, Dog, Horse
LGI2 agaaaatcTGGTCAaaaggaatc intragenic (intron 2) Chimpanzee, Rhesus macaque
ADIPOQ caaaataaGGGTCAaggcctgga from 2243 to 2221 (promoter) Chimpanzee
ADIPOQ cactgagtTGGCCAatgggaaat from 293 to 271 (promoter) Chimpanzee, Mouse
Regulatory regions (600–1100 bp promoters or intragenic regions) of ten human genes displayed by our over-expression experiments were extracted from sequence
databases (Genomatix, UCSC, Genbank) and analyzed for the presence of sequences close to the RORE consensus ((A/T rich)6PuGGTCA). We found that regulatory
regions of nine human genes out of ten contain one or two putative ROREs. The gene symbols are given in column 1. Sequences containing the putative ROREs (in
bold) are in column 2. Positions of these sequences relatively to the transcriptional start sites (TSS; +1) in the human promoters or positions in the intragenic regions are
in column 3. Some promoters contain three possible TSSs (PLG, G6PC, NR1D2, MLLT7, ADIPOQ). In these cases, the positions of the sequences are relative to the
downstream TSS. Species in which the RORE is totally or partially conserved are given in column 4 (the RORE sequences found conserved in the species available in the
databases are shown in Supporting Information S3). No RORE has been found in the human SMOC1 promoter. The human LPA promoter could not be analyzed because
it was not referenced in the Genomatix program.
doi:10.1371/journal.pone.0022545.t002
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physiological states in which RORa may play an important
regulatory role. We show that RORa governs expression of two
other monomeric nuclear receptors of the Rev-erb family. In
addition to Rev-erba known to be a direct RORa target gene
[26,27], we show here that expression of the NR1D2 nuclear
receptor, also known as Rev-erbß, is also controlled by RORa.
This finding is of importance in the field of chronobiology since
RORs and Rev-erbs nuclear receptors constitute essential players
in the circadian clock ([24] and see [22] for review). The
interrelationship between RORs and Rev-erbs nuclear receptors
susceptible to bind to similar DNA target sequences could tightly
control enzymes involved in liver metabolism and whose
expression/activity is known to oscillate as a function of time
throughout the day. In these respects, our finding that Rev-erbß
expression is, at least in part, controlled by RORa adds another
degree to the complexity and consequently to the finely tuned
regulation by the mammalian clock of enzymes and transport
proteins synthesized by the liver, and whose various functions
include lipid metabolism, coagulation/fibrinolysis, etc….
We and others have shown that RORa controls genes encoding
enzymes or transport proteins such as a-fetoprotein [16], ApoA-I
[14], ApoC-III [17], and ApoA-V [18], all of which play key roles
in lipid metabolism/transport. It has also been shown recently that
RORa controls adipocyte differentiation [36]. Our present data
showing that the expression of G6PC, which encodes a subunit of
G6Pase, is controlled by RORa in HepG2 cells are in agreement
with a study showing that G6PC is a RORa target gene in mouse
liver [37]. They agree with the fact that G6Pase is regulated by
Rev-erba [38]. Our results support the notion that RORa may
play a role in controlling the carbohydrate metabolism, besides its
function in lipid metabolism. G6Pase is a key enzyme in the
regulation of hepatic glucose production and blood glucose
homeostasis. It catalyzes the terminal step in the glycogenolytic
and gluconeogenic pathways (see [39] for review). Mutations in the
G6PC gene result in glycogen storage disease type 1a mainly
characterized by hypoglycemia [40]. Tight links between G6Pase
and the insulin regulatory pathway have been reported (see [39]
for review). ADIPOQ, which encodes a protein also involved in
both lipid and glucose metabolism has also been identified as a
RORa target in this study [41]. That RORa and HIF-1a regulate
each other under hypoxic stress [20,21] further supports a role for
RORa in carbohydrate metabolism since it is well known that the
carbohydrate metabolism pathway is greatly altered during the
Figure 5. qPCR analysis of immunoprecipitated chromatin shows that RORa binds to the regulatory regions of SPARC, PLG, G6PC,
NR1D2 and AGRP in HepG2 cells. Chromatin was prepared from stably-transfected HepG2 cells over-producing RORa1 (A) or not (B) and
fragmented by sonication. Chromatin fragments were then immunoprecipitated with a specific anti-RORa antibody (black bars) or with a nonspecific
IgG as a negative control (white bars). qPCR (normalized to input) was used to amplify genomic fragments covering the ROREs identified in silico in
the SPARC, PLG, G6PC, NR1D2 (intron 5) and AGRP genes. qPCR amplification of a DNA region located in the SPARC gene but devoid of RORE was used
as a negative control (SPARCn). Data are represented as the means +/2 S.E.M. (n=3). *: P,0.05, **: P,0.01 between samples treated with the anti-
RORa antibody and samples treated with nonspecific IgG.
doi:10.1371/journal.pone.0022545.g005
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a new role for RORa in controlling carbohydrate metabolism.
We show that the SPARC gene, also known as Osteonectin is a new
RORa target gene. This gene encodes a matricellular protein that
controls cell-cell and cell-matrix adhesion. It may also play a role
in cell growth and, depending on the cell type, this multi-faceted
protein is associated with a highly aggressive tumor phenotype or
behaves as a tumor suppressor (see [28] for review). In
hepatocellular carcinomas, SPARC expression correlates with
tumor angionenesis [43]. Expression of the SPARC gene is up-
regulated in fibrotic liver [44] while its down regulation by
adenoviral expression of an antisense SPARC attenuates liver
fibrosis [45]. Interestingly, SPARC over-expression in hepatocel-
lular carcinoma cells results in a reduced tumorigenicity [46].
Another gene that we found up-regulated by RORa is HEPN1,
which encodes a peptide involved in the control of cell growth and
apoptosis, and whose expression is down-regulated in hepatocel-
lular carcinoma [47]. These data strongly suggest a role for RORa
at different steps of liver carcinogenesis.
In conclusion, our results point to possible roles of the RORa
nuclear receptor in liver cells (lipid and carbohydrate metabolism,
circadian clock, inflammation and carcinogenesis). They also open
new routes to think about a more general role for RORa in
(patho)physiology.
Materials and Methods
Cell culture
HepG2 human hepatoma cells (American Type Culture
Collection HB-8065) were cultured as monolayers at 37uCi na
humidified 95% air/5% CO2 incubator. The culture medium
used was a 1:1 mixture of Dulbecco’s Modified Eagle’s Medium
and Ham-F12 medium with Glutamax-I, supplemented with 10%
(v/v) fetal bovine serum, 100 mg/ml gentamycin, and 2.5 mg/ml
fungizone (all from Invitrogen). HepG2 cells were 70–80%
confluent before use.
Vectors, stable and transient transfections and luciferase
assay
The pCMX-hRORa1 expression vector containing the human
RORa1 cDNA and the pCMX empty vector were from Dr. V.
Gigue `re [7]. The pPGK-neo expression vector contains the
phosphoglycerate kinase 1 promoter driving the neomycin
phosphotransferase gene [48]. The pRORE(hSPARC)3x-Tk-Luc
was obtained by cloning three copies (sense-sense-sense) of the
RORE, located between nucleotides 2274 and 2285 of the
human SPARC promoter in the BglII restriction site in the
polylinker of the TkpGL3 firefly luciferase reporter vector
(referred to as pTk-Luc in the rest of this manuscript and
previously described in [49]). To this aim, the oligonucleotides
hSPARC-RORE3x/U, 59-GATCTGCTGTTCTGGGTCATC-
CCGCTGTTCTGGGTCATCCCGCTGTTCTGGGTCATC-
CCA-39, hSPARC-RORE3x/L, 59-GATCTGGGATGACCCA-
GAACAGCGGGATGACCCAGAACAGCGGGATGACCCA-
GAACAGCA-39were used. Identity of the pRORE(hSPARC)3x-
Tk-Luc vector was verified by DNA sequencing. The pRL-Tk
vector (Promega) contains the herpes simplex virus thymidine
kinase promoter driving the renilla luciferase reporter gene. Stable
transfection experiments were done using the calcium phosphate
precipitation method exactly as described [19]. Transient
transfection experiments were done using the Fugene 6 reagent
(Roche Molecular Biochemicals). Cells cultured in 12-well plates
were co-transfected with 666 ng/well of pTk-Luc or pRORE
(hSPARC)3x-Tk-Luc reporter vector with 0-, 166.5- or 333-ng/
well of pCMX-hRORa1 expression vector. 83 ng of pRL-Tk
expression vector was added in each well in order to normalize
transfection efficiencies. The total amount of transfected DNA was
kept constant to 1082 ng/well by addition of the pCMX insertless
vector. The cells were lysed 48 h after transfection in 200 mlo f
reporter lysis buffer (Promega). Luciferase activity was assayed
using the Dual-Luciferase Reporter Assay System (Promega). The
firefly luciferase activity was normalized with the renilla luciferase
activity.
Adenovirus infection
Recombinant Ad-GFP and Ad-RORa1 were obtained by
homologous recombination in Escherichia coli [50] after insertion
of the cDNAs into the pAdCMV2 vector. Viral stocks were
titrated as previously described [51]. HepG2 cells were infected
overnight at an input multiplicity of 100 virus particles per cell by
adding virus stocks directly to the culture medium. Cells were
harvested 24, 48, 72 hours after the end of the infection for RNA
preparation.
Micro-array analysis
Total RNA was isolated using TRIZOL
TMLS reagent (Invitro-
gen). Preparation of the labeled cDNA samples, hybridization of
oligonucleotide microarrays and data analyzes were performed by
the Diagnogene society (Diagnogene, division of Imaxio, Saint-
Beauzire, France) using the system developed by Agilent
Technology. Briefly, quality and quantity of the total RNA
samples were assessed by measuring the UV absorbance at 260
and 280 nm with a spectrophotometer and performing an
electropherogram with 2100 Bioanalyzer (Agilent Technology).
Then 500 ng of total RNA was used to synthesize fluorescently
labeled cRNA probes by incorporation of cyanine 3- or cyanine 5-
CTP using the low input linear amplification kit (Agilent
Technology), according to the manufacturer’s guidelines. Labeled
cRNA samples were purified with RNeasy mini spin columns
(Qiagen) and the quantity and quality of the cRNA samples were
assessed by measuring the UV absorbance at 260 nm with a
spectrophotometer and performing an electropherogram with
2100 Bioanalyzer (Agilent Technology), respectively. After frag-
mentation, the cRNA samples were hybridized on the slides
(Human Whole Genome Oligonucleotides Microarrays 4644k,
G4112F, Agilent Technology) by using the Gene expression
Hybridization kit (Agilent Technology). Arrays were then scanned
(G2505R scanner, Agilent Technology) allowing simultaneous
reading of the Cy3 and Cy5 fluorophores. The resolution was
5 mm and the settings were PMT cy3 XDR High 100%, Low
10% and PMT cy5 XDR High 100%, Low 10%. Image analysis
was performed with Feature Extraction 9.1.3 software (Agilent
Technology), following the manufacturer’s recommendations
(normalization: linear lowess). The software calculates a p-value
giving the statistical significance on the LogRatio per each gene
between the red and green channels. A gene is considered
differentially expressed between two conditions if the difference is
more than 2 fold and if the Pvalue is less than 0.01 for all the
replicates. Our data from the microarray analysis are deposited in
the GEO repository (accession number GSE18875).
RNA analysis by qRT-PCR
Total RNA was isolated using TRIZOL
TMLS reagent (Invitro-
gen). Quantity of the total RNA samples was assessed by
measuring the UV absorbance at 260 and 280 nm with a
spectrophotometer. Total RNA was reverse-transcribed using the
iScript cDNA Synthesis kit (Biorad). Real-time quantitative PCR
was carried out with the MyiQ Biorad Instrument using the iQ
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according to the manufacturer’s guidelines. Final concentrations of
MgCl2 and primers were 3 mM and 0.3 mM, respectively. The
sequences of the PCR primers and the size of amplicons are shown
in Supporting Information S1. Care was taken to choose these
oligonucleotides in different exons of the respective genes.
Electromobility Shift Assays (EMSAs)
The RORa1 protein was obtained in vitro from the pCMX-
hRORa1 vector using the TNT-T7 Quick coupled transcription/
translation kit (Promega). DNA-protein complexes were allowed to
form by incubating 1 ml of the programmed lysate for 20 min on
ice in a 15 ml reaction containing 15 mM Tris-HCl, pH 7.5,
50 mM KCl, 15 mM NaCl, 1 mM MgCl2, 0.03 mM EDTA,
1 mM dithiothreitol, 7% glycerol (v/v), 50 ng of poly(dI-dC),
50 ng of unspecific single-stranded oligonucleotides and 0.15 ng
(10,000 cpm) of the double-stranded oligonucleotide labeled by
fill-in with the Klenow polymerase and [a-32-P]-dATP (3000 Ci/
mmole, Amersham). For competition experiments, double-strand-
ed oligonucleotides were added simultaneously with the labeled
probe. Electrophoresis was performed at 200 V for 2 h at 15uCi n
0.256 TBE buffer on a native 6% polyacrylamide gel that had
been pre-run for 2 h under the same conditions. The gels were
then fixed for 20 min in 20% ethanol, 10% acetic acid, dried and
submitted to autoradiography.
Chromatin Immunoprecipitation (ChIP)
ChIP was performed as described [52] with some modifications.
Briefly, HepG2 cells were grown to 60% confluence. Cell lysates
corresponding to 50610
6 cells were sonicated on ice 8 times for
1 min each. The sample was divided in two: one half was
immunoprecipitated overnight at 4uC using ProteinA Ceramic
HyperDHF (Pall) and 4 mg of goat anti-RORa antibody (Santa
Cruz Biotechnology, Inc), and the other half was immunoprecip-
itated overnight at 4uC using ProteinA Ceramic HyperDHF (Pall)
and 4 mg of normal goat IgG (Santa Cruz Biotechnology, Inc).
One-sixtieth of the immunoprecipitated DNA was analyzed by
real-time quantitative PCR on an ABI Prism 7500 apparatus using
the Absolute QPCR SYBR Green ROX Mix (Thermo Scientific),
according to the manufacturer’s guidelines. Primers specific for the
genomic regions containing ROREs identified in silico in SPARC,
PLG, G6PC, NR1D2 and AGRP or specific for a genomic region
located in SPARC and devoid of RORE (SPARCn) were used. Final
concentrations of MgCl2 and primers were 3 mM and 0.3 mM,
respectively. The sequences of the PCR primers and the size of
amplicons are shown in Supporting Information S1.
Sequence analysis
For each gene analyzed, the human regulatory regions
(promoter or intragenic region) were extracted from sequence
databases (Genbank; UCSC; ElDorado genome database using
the Gene2Promoter software (Genomatix.de)). The promoter
sequences were numbered relatively to the Transcription Start
Site (TSS). In the case of multiple possible TSS we chose the more
downstream TSS to determine the position of the putative RORE.
The putative ROREs (close to the (A/T rich)6PuGGTCA
consensus sequence) were selected by the MatInspector software
(Genomatix.de) with regard to the 8 validated weight matrices for
RORa or by manual search. For each regulatory region
containing a putative RORE, we searched the conservation of
the putative RORE in the orthologous sequences available in the
ElDorado genome database (among of list of 20 organisms) or in
the UCSC database.
Statistical analysis
qRT-PCR, transfection and ChIP results are expressed as
means 6 S.E.M. for the number of experiments indicated in each
case. Statistical analysis was performed using the ANOVA test
followed by the Scheffe post-hoc test (Statview F-4.5 and Analyse-it
softwares). A Pvalue of less than 0.05 (*), 0.01 (**) or 0.001 (***)
indicated significance.
Supporting Information
Supporting Information S1 PCR primers used in the
qRT-PCR experiments (Table). Gene names, sequences of
the forward and reverse PCR primers, size of the PCR amplicon
and the corresponding Genbank accession number are shown.
qPCR primers used in the ChIP experiments (Table).
Gene names, sequences of the forward and reverse qPCR primers
and size of the PCR amplicon are shown.
(DOC)
Supporting Information S2 Micro-array analysis of the
effects of a stable RORa over-expression on gene
expression in HepG2 cells (Table). Complementary Table
to Table 1 showing all the sequences (sequences corresponding to
known genes and sequences not assigned to a known gene) found
either up- or down-regulated in response to RORa over-
expression. HepG2 cells were stably transfected with the
pCMX-hRORa1 expression vector or with the pCMX insertless
vector as a control. Total RNAs were extracted and mRNA levels
were compared between these two experimental conditions with
Agilent micro-arrays (n=3 independent pools of transfected cells).
This analysis revealed several genes whose expression was up-
regulated or down-regulated by at least 2 fold in cells
overexpressing RORa as compared to control cells. The gene
symbols, gene description, genbank accession numbers and feature
numbers on micro-arrays are given in columns 1 to 4. Gene
expression levels in RORa over-expressing cells are expressed
relatively to those in control cells. Results are given as fold changes
(columns 5, 7, 9) and corresponding Pvalues (columns 6, 8, 10).
The means and S.E.M. of the fold changes are given in columns
11 and 12. All Pvalues are less than 0.01 except one over three for
AGRP.
(PDF)
Supporting Information S3 Conservation in different
species of the ROREs identified in the human genes
(Table). Analysis of the ROREs was performed as described in
Materials and Methods. The gene symbols and the species are
given in column 1. In the case of genes whose regulatory sequences
contain two putative ROREs the gene symbol is followed by the
number of the RORE (21o r22). Sequences containing the
putative ROREs (in bold) are in column 2.
(DOC)
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